G1 Therapeutics stock (US36192T1060): Biotech innovator in oncology treatments

G1 Therapeutics Inc develops novel cancer therapies targeting cell cycle regulation. US investors track the company for its pipeline progress in small cell lung cancer and potential regulatory milestones amid biotech sector volatility.

G1 Therapeutics Inc focuses on oncology therapeutics that target the cell cycle to improve cancer treatment outcomes. The company trades on Nasdaq under the ticker GTHX. Shares have shown volatility typical of clinical-stage biotechs, with recent trading at around $1.50 USD on 05/14/2026 on Nasdaq, according to Yahoo Finance as of 05/14/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: G1 Therapeutics Inc
• Sector/industry: Biotechnology / Oncology
• Headquarters/country: United States
• Core markets: US, global oncology
• Key revenue drivers: Trilaciclib commercialization, pipeline milestones
• Home exchange/listing venue: Nasdaq (GTHX)
• Trading currency: USD

G1 Therapeutics: core business model

G1 Therapeutics Inc is a clinical-stage oncology company developing drugs that protect healthy cells during chemotherapy. Its lead product, trilaciclib, is a CDK4/6 inhibitor designed to reduce myelosuppression in patients receiving chemotherapy for small cell lung cancer (SCLC). The company received FDA approval for trilaciclib (Cosela) in February 2021 for use with specific chemotherapy regimens in extensive-stage SCLC, according to company press release as of 02/12/2021. This approval marked a key milestone, enabling commercialization efforts targeted at US oncology practices.

The business model centers on partnering with chemotherapy providers to integrate trilaciclib into standard care protocols. G1 Therapeutics generates revenue primarily from Cosela sales in the US market, where SCLC represents a significant unmet need due to high toxicity of first-line treatments. The company reported $25.6 million in Cosela net sales for full-year 2023 (period ending 12/31/2023, reported 03/12/2024), per Q4 2023 earnings release as of 03/12/2024. Ongoing pipeline work includes expansion into triple-negative breast cancer and colorectal cancer.

Main revenue and product drivers for G1 Therapeutics

Trilaciclib remains the primary revenue driver, with sales growth driven by increased adoption in community oncology settings. The drug addresses chemotherapy-induced neutropenia, a common side effect limiting treatment efficacy. For Q3 2024 (period ending 09/30/2024, reported 11/07/2024), G1 reported $6.5 million in Cosela revenue, up 8% year-over-year, according to Q3 2024 earnings release as of 11/07/2024. This reflects steady market penetration despite competitive CDK4/6 landscape.

Beyond Cosela, pipeline candidates like G1T48 (oral CDK4/6 inhibitor) target metastatic breast cancer. Phase 2 data presented at ESMO 2023 showed promising progression-free survival, per company announcement as of 10/20/2023. These developments support long-term revenue potential through label expansions and new indications.

Industry trends and competitive position

The oncology sector sees robust demand for supportive care therapies amid rising cancer incidence. US new cancer cases reached 2 million in 2024 per American Cancer Society as of 01/17/2024. G1 Therapeutics competes with established players like Pfizer's Ibrance in CDK4/6 space but differentiates via short-course IV administration for chemo protection. Its focus on SCLC, affecting ~45,000 US patients annually, positions it in a niche with limited alternatives.

Biotech funding trends favor companies with approved products and clean safety profiles. G1's cash position stood at $52.1 million as of Q3 2024 end, sufficient for operations into 2026, per earnings release cited above. Partnerships, such as with Janssen for Asian rights (announced 2022), bolster global reach.

Why G1 Therapeutics matters for US investors

G1 Therapeutics offers US investors exposure to innovative oncology supportive care, a $10B+ market growing at 8% CAGR through 2030 per Grand View Research as of 2024. Listed on Nasdaq, it provides direct access to biotech upside from clinical and commercial catalysts. With ~50% of revenue from US hospitals, the stock ties to domestic healthcare spending trends.

Conclusion

G1 Therapeutics continues advancing its CDK4/6 inhibitor platform with Cosela sales providing a revenue base amid pipeline expansion efforts. Recent quarterly results show commercial traction in SCLC, while ongoing trials could unlock new markets. Investors monitor regulatory updates and sales execution for potential inflection points in this volatile biotech space.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.